[go: up one dir, main page]

AR059088A1 - Administracion intraventricular de una proteina para esclerosis lateral amiotrofica - Google Patents

Administracion intraventricular de una proteina para esclerosis lateral amiotrofica

Info

Publication number
AR059088A1
AR059088A1 ARP070100238A ARP070100238A AR059088A1 AR 059088 A1 AR059088 A1 AR 059088A1 AR P070100238 A ARP070100238 A AR P070100238A AR P070100238 A ARP070100238 A AR P070100238A AR 059088 A1 AR059088 A1 AR 059088A1
Authority
AR
Argentina
Prior art keywords
lateral sclerosis
protein
intraventricular administration
amiotrophic lateral
amyotrophic lateral
Prior art date
Application number
ARP070100238A
Other languages
English (en)
Inventor
James Dodge
Ronald K Scheule
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR059088A1 publication Critical patent/AR059088A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La esclerosis lateral amiotrofica puede tratarse exitosamente usando la aplicacion intraventricular de un factor de crecimiento neurotrofico, IGF-1. La administracion puede realizarse lentamente para lograr el efecto máximo. Los efectos pueden observarse en ambos lados de la barrera sangre-cerebro, por lo cual este medio de aplicacion para esclerosis lateral amiotrofica afecta a ambos, el cerebro y el musculo esquelético.
ARP070100238A 2006-01-20 2007-01-19 Administracion intraventricular de una proteina para esclerosis lateral amiotrofica AR059088A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76037706P 2006-01-20 2006-01-20

Publications (1)

Publication Number Publication Date
AR059088A1 true AR059088A1 (es) 2008-03-12

Family

ID=38288299

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100238A AR059088A1 (es) 2006-01-20 2007-01-19 Administracion intraventricular de una proteina para esclerosis lateral amiotrofica

Country Status (10)

Country Link
US (1) US20090105141A1 (es)
EP (1) EP1986680A4 (es)
JP (1) JP2009523819A (es)
CN (1) CN101443029A (es)
AR (1) AR059088A1 (es)
BR (1) BRPI0706694A2 (es)
CA (1) CA2636438A1 (es)
IL (1) IL192678A0 (es)
RU (1) RU2008134118A (es)
WO (1) WO2007084743A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641359C (en) 2006-02-09 2022-10-04 Genzyme Corporation Slow intraventricular delivery
BRPI0910338A2 (pt) * 2008-04-03 2020-08-18 F. Hoffmann-La Roche Ag uso de variantes peguiladas de igf-i para o tratamento de distúbios neuromusculares
US10140708B2 (en) * 2016-01-21 2018-11-27 Riverside Research Institute Method for gestational age estimation and embryonic mutant detection
US20210198312A1 (en) * 2019-12-31 2021-07-01 Helena Lovick Growth factor concentrate and method of manufacture thereof
WO2023242442A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) * 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5858966A (en) * 1994-12-21 1999-01-12 Auckland Uniservices Limited Fetal growth
WO1997039789A1 (en) * 1996-04-22 1997-10-30 Medtronic, Inc. Two-stage angled venous cannula
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US20060014166A1 (en) * 2004-01-27 2006-01-19 Yossi Cohen Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis

Also Published As

Publication number Publication date
EP1986680A4 (en) 2010-12-08
JP2009523819A (ja) 2009-06-25
EP1986680A2 (en) 2008-11-05
BRPI0706694A2 (pt) 2011-04-05
WO2007084743A3 (en) 2008-11-27
WO2007084743A2 (en) 2007-07-26
RU2008134118A (ru) 2010-02-27
CA2636438A1 (en) 2007-07-26
CN101443029A (zh) 2009-05-27
US20090105141A1 (en) 2009-04-23
IL192678A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
AR059089A1 (es) Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
NL300936I2 (nl) Semaglutide
AR059088A1 (es) Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
GB2437639B (en) Privacy enhanced identity scheme using an un-linkable identifier
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
DE602005001512D1 (de) System zur intravenösen Verabreichung
LT2959894T (lt) S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
ATE537844T1 (de) Dauerhafte lokalanästhetische zusammensetzung mit saib
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
TWI377955B (en) Processes for preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
EP1946413A4 (en) HIGH END PUMPING PUMP LASER WITH OUTER PIPING
EP2208498B8 (en) Pharmaceutical composition combining various venotonic and vasoprotective agents for the treatment of chronic venous insufficiency
ITMI20080038A1 (it) Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva
HUE039554T2 (hu) Készítmények krónikus degeneratív gyulladásos állapotok kezelésére
NO20053947D0 (no) Forbedrede antitumorale behandlinger.
CL2008003933A1 (es) Compuestos derivados de n-heterociclo-[1,2-a]-piridina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
EP2167071A4 (en) BACLOFEN SOLUTION FOR LOW VOLUME THERAPEUTIC DELIVERY
DE502006001195D1 (de) Transdermales therapeutisches system zur verabreichung von analgetika
CL2008003931A1 (es) Compuestos derivados de n-fenil-imidazo-[1,2-a]-piridin-2-carboxamida sustituido; compuestos intermediarios; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
ITRE20040055A1 (it) Bocchetta per vasche da idromassaggi
BRPI0810682A2 (pt) agente antitumoral em especial para o tratamento de tumores dérmicos, fármaco, kit compreendendo fármaco.
BRPI1008207A2 (pt) "composição farmacêutica para tratamento de efeitos colateriais por administração de spiegelmers."
DE502005000548D1 (de) Common-Rail-Injektor
ITBO20060233A1 (it) Apparecchiatura ausiliaria per trattamenti dentali.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal